Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00016744

Recruitment Status : Completed

First Posted : June 4, 2001

Last Update Posted : January 9, 2009

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Cystic Fibrosis Foundation

National Center for Research Resources (NCRR)

Information provided by:

Children's Hospital of Philadelphia

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	October 2005
Actual Study Completion Date :	October 2005

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.

To Top